[PDF] Top 20 Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Has 10000 "Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma" found on our website. Below are the top 20 most common "Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma".
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... observed PD-L1 expression in 88% of newly diagnosed and ...recurrent glioblastoma specimens [13]. Similarly, Nduom et al. measured PD-L1 expression in 94 glioblastoma patients ... See full document
13
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
... Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of ...cancers. PD-L1 is constitutively expressed in ... See full document
8
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
... evaluate PD-L1 expression in situ resolves the practical issues encountered with ...the PD-L1 status during the course of treatment is feasible, thereby aiding decisions to continue or stop ... See full document
12
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
... safe immunotherapy that can be enhanced by anti PD-1/PD-L1 ...and PD-1 blockade combination therapy, the future implementation of rational combinatorial therapy ... See full document
13
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
... Clinically apparent cancer can be thought of as a host’s inability to eliminate transformed cells. Cancer im- munotherapy refers to a diverse range of therapeutic approaches that harness the immune system to induce or ... See full document
21
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
... immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor ...the PD-1/PD-L1 axis for immune escape to facilitate tumor growth, which can be ... See full document
8
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
... immune- checkpoint inhibitors in combination with DNA damaging chemotherapies (Figure ...immune checkpoint inhibitor (Figure ...of immunotherapy/chemotherapy trials being conducted over the last ... See full document
41
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
... defined residues 591, 609, 636–638, 653 as putative binding sites to investigate the binding of niclosamide to STAT3. The docking simulations were carried out using Surflex module of SYBYL software (Tripos, Inc), which ... See full document
13
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy
... Sentinel LN resection is still common clinical practice in many forms of cancer to determine disease staging and consecutive therapy options, and when metastases are detectable in the sentinel LN, resection of several, ... See full document
7
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
... immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including ... See full document
5
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
... and PD-1/PD-L1 ...and checkpoint blockade beyond those expected with either modality alone [121, 124, ...with PD-1 or CTLA-4 blockade identified ... See full document
17
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
... of, potential long-term anti-tumor immunity after administration of anti-PD-1, an immune checkpoint ...[27]. PD-L1 expression on tumor cells and immune cells has been shown to ... See full document
5
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
... death 1 (PD-1) receptor, an immune checkpoint expressed on exhausted effector T lymphocytes, and prevents binding by its activating ligand PD-L1, leading to reinvigoration of ... See full document
7
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
... death 1 (PD-1) and its ligands, programmed death-ligand (PD-L) 1 and 2, are members of the B7/CD28 ligand–receptor family and represent the most investigated inhibitory immune ... See full document
15
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
... The purpose of exploring combined interventions is to combine specific antitumor modalities to enhance thera- peutic effects. However, this must be an evidence-based investigation to reduce both risk and harm. In ... See full document
21
T cell Bim levels reflect responses to anti–PD-1 cancer therapy
... whether Bim could be used as a noninvasive monitoring or predictive biomarker to evaluate T cell responses in patients with cancer undergoing treatment with an anti–PD-1 monoclonal antibody. Among the 38 ... See full document
15
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
... Leukemia, particularly aggressive refractory hematological malignancies unresponsive to upfront therapy, remains a difficult condition to treat. The focus of therapy is to achieve complete disease remission. Therefore, ... See full document
6
PD L1 on host cells is essential for PD L1 blockade–mediated tumor regression
... of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1–negative patients also respond to this ...whether PD-L1 on tumor or host ... See full document
10
<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>
... However, DCs often do not function ef fi ciently in the tumor environment. The tumor microenvironment can affect the distribution, differentiation, and maturation of DCs. (1) The tumor microenvironment affects DCs ... See full document
12
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
... Three tissue microarray (TMA) slides were used to evaluate the expression patterns of the PD-1 axis. One was con- structed using samples acquired from the Musculoskeletal Tumor Center, Peking University ... See full document
13
Related subjects